Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380932 | 0.86 | PTK2 (0.52) | LRRK2PTK2TTK | |
| SCHEMBL16995419 | 0.83 | PTK2 (0.53) | LRRK2PTK2TTK | |
| SCHEMBL12745451 | 0.83 | NPC1 (0.43) | PTK2 | |
| SCHEMBL1466613 | 0.78 | LRRK2 (0.51) | LRRK2PTK2TTK | |
| SCHEMBL1467078 | 0.78 | LRRK2 (0.51) | LRRK2PTK2ALKTTK | |
| SCHEMBL12745482 | 0.78 | LRRK2 (0.51) | LRRK2PTK2TTK | |
| SCHEMBL12745485 | 0.78 | LRRK2 (0.51) | LRRK2PTK2ALKTTK | |
| SCHEMBL2637182 | 0.76 | ALK (0.46) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL10205847 | 0.76 | PTK2 (0.53) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL14331596 | 0.76 | PTK2 (0.53) | LRRK2PTK2JAK2NTRK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408752-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-08-12 | — | — | EP | disclosed |
| EP-2435411-B1 | 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20110275633-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010106097-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010055117-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051674-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LRRK2 1540/4885PTK2 1621/4885JAK2 422/4885 |
| US-20110275633-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PTK2B, CDK2, PTK2 | LRRK2 821/4885PTK2 3/4885JAK2 116/4885 |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | RB1, MKI67, CCNA1 | LRRK2 2645/4885PTK2 956/4885JAK2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.